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Abstract
Depressive symptoms are common in glioma patients, and can negatively affect health-related quality of life (HRQOL). We per-
formed a nation-wide randomized controlled trial to evaluate the effects of an online guided self-help intervention for depressive 
symptoms in adult glioma patients. Glioma patients with depressive symptoms were randomized to a 5-week online course based 
on problem-solving therapy, or a waiting list control group. After having received the intervention, the glioma patient groups 
combined were compared with patients with cancer outside the central nervous system (non-CNS cancer controls), who also 
received the intervention. Sample size calculations yielded 63 participants to be recruited per arm. The primary outcome [depres-
sive symptoms (CES-D)] and secondary outcomes [fatigue (Checklist Individual Strength (CIS)) and HRQOL (Short Form-36)], 
were assessed online at baseline, post-intervention, and 3 and 12 months follow-up. In total, 89 glioma patients (intervention 
N = 45; waiting list N = 44) and 26 non-CNS cancer controls were included, of whom 35 and 54% completed the intervention, 
respectively. Recruitment could not be extended beyond 3.5 years due to funding. On depression, no statistically significant dif-
ferences between the groups were found. Fatigue decreased post-treatment in the glioma intervention group compared with the 
waiting list group (p = 0.054, d = 0.306). At 12 months, the physical component summary (HRQOL) remained stable in glioma 
patients, while scores improved in non-CNS cancer controls (p = 0.035, d = 0.883). In this underpowered study, no evidence for 
the effectiveness of online guided self-help for depression or HRQOL in glioma patients was found, but it may improve fatigue.
Trial registration Netherlands Trial Register NTR3223.
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Introduction
Following the diagnosis of glioma, many patients experience 
depressive symptoms. Indeed, systematic reviews and longi-
tudinal studies suggest that ~ 15–20% of glioma patients will 
develop a depressive disorder during the first 8 months after 
diagnosis [1, 2]. The increased risk may be maintained up to 
a year after initial surgery [3]. Depression can have serious 
negative consequences for glioma patients’ health related 
quality of life (HRQOL) [4].
A number of tumor- and treatment-related mechanisms, 
including tumor location [5], elevated intracranial pressure 
[6], biochemical changes [7], changes in cytokine levels [8], 
use of antiepileptics [9], and corticosteroids [10] have been 
suggested to contribute to depression in glioma patients, 
although the underlying mechanisms are not well under-
stood [7, 11]. Patients’ emotional reactions to the diagnosis 
and poor prognosis of the disease may contribute consider-
ably [12–14]. Health care professionals may find it difficult 
to discuss depressive symptoms especially when these are 
understandable [15], leaving depressive symptoms that are 
potentially treatable, untreated [16].
(Inter)national guidelines suggest that depression in 
patients with chronic physical conditions should be treated 
with a combination of medication and psychological treat-
ment such as cognitive behavioral therapy (CBT) [17, 18]. 
However, a lack of randomized controlled trials (RCTs) in 
glioma patients makes it difficult to gauge whether these 
treatment strategies should also be pursued in patients with 
a brain tumor [19]. Glioma patients are at high risk for cog-
nitive deficits and fatigue, and may struggle to fully benefit 
from CBT. Antidepressant treatment brings the possibility 
of adverse drug interactions, introducing a reluctance in both 
physicians and patients to initiate new pharmaceutical treat-
ment [20].
The present RCT therefore aimed at decreasing depres-
sive symptoms by means of a low-intensity form of CBT 
[i.e., guided self-help based on problem-solving therapy 
(PST)], delivered online to increase accessibility and to 
lower the experienced barrier to mental health care. Inter-
net-based psychological interventions, including PST, have 
already been found to be equally effective as face-to-face 
treatment to decrease depressive symptoms in people from 
the general population [21, 22]. As depression may inter-
act with functional activities and health-related quality of 
life (HRQOL), the effects of the internet-based therapy on 
fatigue and overall HRQOL were also evaluated. If proven 
effective, this online guided self-help intervention could 
improve psychological care for glioma patients.
Methods
Design
This RCT was aimed at evaluating the effects of an inter-
net-based guided self-help intervention targeting depres-
sive symptoms in glioma patients. We compared a group 
of glioma patients who received the intervention immedi-
ately (glioma intervention group; GI group) with a 12 week 
waiting list control group (glioma waiting list group; GWL 
group), and with a non-CNS cancer control group (who also 
receive the intervention; non-CNS cancer control group). A 
detailed study protocol has been published previously [23], 
no changes have since been made. The institutional review 
board of the VU University Medical Center approved the 
study protocol (registration number 2011/227). The trial was 
registered in the Netherlands Trial Registry (NTR3223).
Participants
Between November 2011 and June 2015, patients from 
31 hospitals throughout the Netherlands were invited to 
participate (see Acknowledgments). In each hospital, tai-
lored operating procedures were installed for approaching 
local patients. Furthermore, advertisements were placed on 
selected websites, and patient associations helped spread 
study information. The recruitment period could not be 
extended due to funding. Data collection was finished in 
June 2016.
Patients who expressed interest in the study completed 
online screening questionnaires: the Beck Scale for Suicide 
Ideation (BSS) [24] and the Center for Epidemiological 
Studies Depression Scale (CES-D) [25]. Adult (> 18 years 
of age) glioma patients with WHO grade II, III or IV glioma, 
and at least mild depressive symptoms (CES-D score ≥ 12) 
were invited to participate. Similarly, adult (> 18 years of 
age) patients with non-Hodgkin lymphoma (NHL), chronic 
lymphatic leukemia (CLL), multiple myeloma (MM), or a 
myelodysplastic syndrome (MDS) and at least mild depres-
sive symptoms (CES-D score ≥ 12) were invited to partici-
pate. Exclusion criteria were (1) no access to the internet 
and/or no email address; (2) insufficient proficiency of the 
Dutch language; (3) suicidal intent as screened for with the 
BSS and followed-up by telephone if needed to check the 
severity of symptoms. If patients were excluded based on 
suicidal intent, their primary care physician was informed. 
All participants provided written informed consent.
Sample size calculation and randomization
A priori sample size calculations yielded 63 patients to be 
included per arm (Cohen’s d = 0.50; 1 − β = 0.80, α = 0.05, 
25% dropout). A concealed, simple adaptive randomization 
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technique (a folded ticket drawn from a concealed box), was 
used to allocate glioma patients to the GI or GWL group 
after baseline assessment. GWL patients could take part in 
the intervention after a 12-week interval. Patients in the GI 
group and the non-CNS cancer control group could take part 
in the intervention directly following baseline assessments. 
Due to the nature of the study, participants nor researchers 
could be blind to group allocation.
Intervention
The intervention was an adaptation of a 5 week online 
guided self-help course founded on the principles of PST 
(‘Everything under control’) [26]; disease-specific infor-
mation and examples were added to the program. The 
intervention consisted of five modules with examples and 
exercises (see Fig. 1 and the published protocol [23]). Dur-
ing the intervention, patients described what they felt to be 
important in their lives, they made a list of their problems 
and concerns, and worked on improving coping strategies 
to deal with these issues. Online support from a coach (a 
researcher-psychologist (FWB), nurse, or a trained and 
supervised psychology student) was provided to facilitate 
successful completion of the intervention. This consisted of 
feedback on completed exercises within 3 working days and 
additional support on request. Follow-up took place at regu-
lar intervals and continued until 12 months after baseline, 
see Fig. 2. Assessments included patient-reported outcome 
measures completed online, but could be sent by mail if 
requested by participants.
Patient‑reported outcomes
Primary outcome
Depressive symptoms The change in depressive symptoms 
as measured with the CES-D [25] at 3 months (GI vs GWL 
groups) and at 3 and 12 months (total glioma vs non-CNS 
cancer controls) was the primary outcome measure. This 
20-item scale is designed to measure the major components 
of depressive symptomatology and has good psychometric 
properties in cancer patient populations [27]. Higher scores 
indicate more depressive symptoms (range 0–60), with the 
usual cut-off score for depression set at ≥ 16.
Secondary outcomes
Fatigue Fatigue was assessed with the 20-item Checklist 
Individual Strength (CIS) [28]. Total fatigue scores range 
from 20 to 140, with higher scores indicating worse func-
tioning. Scores ≥ 76 are indicative of severe fatigue.
Health-related quality of  life The Short-Form Health Sur-
vey (SF-36) [29] was used to assess HRQOL. The 36 items 
can be used to calculate two higher-order summary scores 
which represent physical health (Physical Component 
Summary; PCS) and mental health (Mental Component 
Summary; MCS). In a normative sample from the general 
population, PCS and MCS scores have a mean of 50 with a 
standard deviation of 10. To assess disease-specific HRQOL 
in glioma patients, the EORTC Brain Cancer Module 
(EORTC BN20) [30] was used. Four multi-item scales can 
be calculated (future uncertainty; visual disorders; motor 
dysfunctions; communication deficits) and seven single 
items representing common symptoms. Scale scores range 
from 0 to 100 with higher scores indicating more symptoms. 
By error, only 18 of the 20 items of this scale were admin-
istered, therefore the motor dysfunction scale and the single 
item bladder control scores could not be calculated.
Cognitive functioning The six item MOS cognitive func-
tioning scale [31] was used to assess everyday problems in 
cognitive functioning (range 6–36). Higher scores indicate 
more cognitive complaints.
Use of  supportive care The Trimbos/iMTA questionnaire 
for Costs associated with Psychiatric Illness (TIC-P) [32] 
was administered initially with cost effectiveness analysis 
in mind. Only the questions relating to supportive care use 
were used.
Patient satisfaction Satisfaction with the intervention was 
assessed by means of a study specific questionnaire. The 
perceived usability, readability, the quality of the content 
Fig. 1  The five modules of the intervention
 Journal of Neuro-Oncology
1 3
Fig. 2  Flow diagram of the study
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and usefulness of the online program, and the coaches’ feed-
back was assessed.
Statistical analysis
All analyses were performed using SPSS software version 
22. Patient-reported outcomes were transformed into scale 
scores. ANOVAs and Chi Square tests were performed to 
compare demographics and clinical variables (age, sex, diag-
nosis, tumor grade, treatments, disease status, supportive 
care use, medication, epilepsy, disease-specific symptoms, 
and cognitive complaints) between the GI and GWL groups. 
Similarly, age, gender, disease status, and current medication 
(except use of antiepileptics), were compared between the 
total glioma group and the non-CNS cancer controls. Chi 
Square tests and descriptive statistics were used to analyze 
adherence, reasons for dropout, and patient satisfaction. For 
descriptive purposes, the percentage of participants scor-
ing above the cut-off for depression (CES-D ≥ 16), fatigue 
(CIS ≥ 76), and diminished HRQOL (MCS and PCS ≤ 40) 
was calculated at each time point.
To compare the effects of the intervention to a waiting list 
only, results from the GI group vs the GWL group at 6 weeks 
(post intervention) and 12 weeks compared to baseline were 
analyzed with linear mixed models (LMMs). To compare the 
effects of the intervention between glioma patients and non-
CNS cancer controls, we added the following assessments 
to form one glioma patient group (‘total glioma group’) that 
participated in the intervention: T0 (GI group) plus T12 
(GWL group); post intervention assessment: T6 (GI group) 
plus T18 (GWL group); 12 weeks assessment: T12 (GI 
group) plus T24 (GWL group); 12 months assessment: T52 
(GI group) plus T64 (GWL group); see Fig. 2. Results from 
this total glioma group vs the non-CNS cancer group at post 
intervention, 12 weeks and 12 months follow-up compared 
with baseline were also analyzed with LMMs. This statis-
tical method copes well with missing observations due to 
dropout, therefore missing data were not otherwise imputed. 
Subjects were added as random effect and interaction, time 
and group were fixed effects, and a time × group interaction 
term was used. Toeplitz covariance structures were applied. 
To correct for baseline differences between the groups, the 
baseline scores of relevant outcome measures (CES-D score, 
CIS total fatigue score, SF-36 MCS/PCS) and variables that 
were significantly different (GI vs GWL group: BN20 future 
uncertainty scale; total glioma group vs non-CNS cancer 
group: patient age) were added as covariates. Both inten-
tion-to-treat (ITT) and per protocol (PP) analyses were per-
formed for depression, fatigue, and HRQOL (MCS and PCS 
scores). As it is yet unclear how many modules are required 
for an effect to be found, all participants who had completed 
≥ one module were included in the PP analyses. P < 0.05 
was considered statistically significant. A Cohen’s d effect 
size based on the difference in sample means and the pooled 
pretest standard deviation, corrected for bias, was calculated 
(0.10–0.29 low; 0.30–0.50 moderate; > 0.50 high) [33, 34].
Results
Participants
In total, we received 308 responses through email, phone 
calls, or (in)complete screening questionnaires, see Fig. 2 for 
consort flow diagram. Of these, 145 patients could be invited 
for participation in the study (78.6% glioma, 21.4% non-
CNS cancer) and 122 patients agreed to participate (78% 
glioma, 22% non-CNS cancer). Before baseline assessment, 
6 glioma patients and 1 non-CNS cancer patient dropped 
out. In total, 89 glioma patients were randomized to either 
the GI group (N = 45) or the GWL group (N = 44), and 26 
non-CNS cancer controls participated.
The majority of patients were women and had middle 
to high levels of education, see Table 1. Glioma patients 
most often suffered from a grade II tumor. Approximately 
76% of glioma patients were using antiepileptic drugs. GWL 
patients experienced more uncertainty concerning the future 
(M = 52.1, SD = 21.7) than GI patients (M = 42.6, SD = 19.6, 
p = 0.033). No other statistically significant differences were 
observed.
Most non-CNS cancer controls were diagnosed with a 
non-Hodgkin lymphoma (46.2%), other diagnoses were 
chronic lymphatic leukemia (11.5%), multiple myeloma 
(11.5%) and myelodysplastic syndrome (11.5%). Non-
CNS cancer controls were older than patients with glioma 
(M = 52.8, SD = 9.3 vs M = 45.0, SD = 11.9 p = 0.003); no 
other statistically significant differences between the groups 
were observed. Outside hospital appointments, patients in all 
groups reported visiting their primary care physician, com-
pany physician, physiotherapist, psychologist/psychiatrist/
counsellor, social worker, substance abuse coach, alternative 
healer, and self-help group (no statistically significant dif-
ferences, see Table 1).
Effects of the intervention on depression, fatigue 
and HRQOL
Figure 3a, b illustrate the percentage of patients scoring 
above the cut-off for depression, fatigue, and diminished 
HRQOL at the different time points.
Glioma intervention group vs. glioma waiting list control 
group
No statistically significant differences in depression scores 
were found between the GI group and GWL group (Table 2).
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Table 1  Clinical and demographic characteristics of study sample
Glioma inter-
vention group
N = 45
Glioma waiting list 
control group
N = 44
P value Glioma total group
N = 82
Non-CNS 
control group
N = 26
P value
Age M (SD) 43.58 (11.69) 46.43 (12.28) 0.265 44.88 (11.97) 52.81 (9.28) 0.003*
Sex N (%)
 Male 19 (42.2%) 18 (40.9%) 0.536 37 (45.1%) 9 (34.6%) 0.345
 Female 26 (57.8%) 26 (59.1%) 45 (54.9%) 17 (65.4%)
Educational level N (%)
 Low 4 (8.9%) 6 (13.6%) 0.734 8 (9.8%) 0 (0%) 0.252
 Middle 21 (46.7%) 18 (40.9%) 36 (43.9%) 13 (50.0%)
 High 20 (44.4%) 20 (45.5%) 38 (46.3%) 13 (50.0%)
Medication use at start of  studyb N (%)
 Antidepressants 5 (11.1%) 5 (11.4%) 0.970 9 (10.9%) 3 (11.5%) 0.937
 Antipsychotics 1 (2.2%) 0 (0%) 0.320 1 (1.2%) 0 (0%) 0.572
 Psychostimulants 0 (0%) 0 (0%) N/a 0 (0%) 1 (3.8%) 0.074
 Antiepileptics 35 (77.8%) 33 (75.0%) 0.758 63 (76.8%) 0 (0%) N/a
 Corticosteroids 3 (6.7%) 4 (9.1%) 0.671 6 (7.3%) 3 (11.5%) 0.497
 Benzodiazepines 8 (17.8%) 6 (13.6%) 0.592 13 (15.9%) 4 (15.4%) 0.954
 Mild opioid analgesics 1 (2.2%) 0 (0%) 0.320 1 (1.2%) 1 (3.8%) 0.387
Disease status during  studyc N (%)
 Stabile disease or remission 29 (64.4%) 31 (70.5%) 0.600 56 (68.3%) 11 (42.3%) 0.278
 Disease progression 6 (13.3%) 6 (13.6%) 10 (12.2%) 2 (7.7%)
 Active treatment 10 (22.2%) 6 (13.6%) 15 (18.3%) 7 (26.9%)
Other support in the past 4 weeks (at baseline) N (%)
 Primary care physician 17 (37.8%) 19 (43.2%) 0.669 36 (43.9%) 11 (42.3%) 1.000
 Psychologist, psychiatrist, or counsellor 13 (28.9%) 11 (25%) 0.813 24 (29.3%) 11 (42.3%) 0.155
 Social worker 3 (6.7%) 5 (11.4%) 0.479 8 (9.8%) 3 (11.5%) 0.711
 Alcohol/drugs coach 1 (2.2%) 0 (0%) 1.000 1 (1.2%) 0 (0%) 1.000
 Self-help group 1 (2.2%) 5 (11.4%) 0.106 6 (7.3%) 3 (11.5%) 0.424
 Company physician 10 (22.2%) 6 (13.6%) 0.410 16 (19.5%) 4 (15.4%) 1.000
 Physiotherapist 10 (22.2%) 9 (20.5%) 1.000 19 (23.2%) 7 (26.9%) 0.599
 Alternative healer 5 (11.1%) 5 (11.4%) 1.000 10 (12.2%) 6 (23.1%) 0.194
Tumor  typea N (%)
 Pontine glioma 0 (0%) 1 (2.3%) 0.707
 Ganglioglioma 1 (2.2%) 0 (0%)
 Astrocytoma 21 (46.7%) 17 (38.6%)
 Oligodendroglioma 10 (22.2%) 11 (25.0%)
 Oligoastrocytoma 6 (13.3%) 7 (15.9%)
 Glioblastoma 6 (13.3%) 7 (15.9%)
 Unspecified glioma 1 (2.2%) 0 (0%)
 Meningioma 0 (0%) 1 (2.3%)
Glioma grade N (%)
 Grade II 26 (57.8%) 23 (52.3%) 0.898
 Grade III 13 (28.9%) 13 (29.5%)
 Grade IV 6 (13.3%) 7 (15.9%)
Epilepsy N (%)
 Yes 23 (51.1%) 23 (52.3%) 0.913
 No 22 (48.9%) 21 (47.7%)
Type of surgery N (%)
 None 0 (0%) 1 (2.3%) 0.168
 Biopsy 4 (8.9%) 9 (20.5%)
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Fatigue scores decreased between baseline and 6 weeks 
(post-intervention) in the GI group compared with the GWL 
group (p = 0.054, d = 0.306; intention to treat analysis only). 
No other statistically significant results were found when 
comparing the GI group and the GWL control group.
Total glioma group vs. non-CNS control group
No statistically significant differences in depression scores 
were found between the total glioma group and the non-CNS 
cancer group (Table 3).
Both intention to treat and per protocol analysis yielded 
statistically significant change with a large effect size in the 
PCS score between baseline and 12 months follow-up (ITT: 
p = 0.035, d = 0.883; PP: p = 0.053; d = 0. 744) with scores 
remaining stable in glioma patients, while improving in non-
CNS cancer controls. No other statistically significant results 
were found between the total glioma group and the non-CNS 
cancer control group.
Intervention adherence and satisfaction
Adherence to the intervention was lower in the total glioma 
patient group (N = 82) compared to non-CNS cancer con-
trols (p = 0.043). In glioma patients, intervention adherence 
was 85% for the introduction and 77, 52, 40, 37 and 35% 
for modules 1 through 5, respectively. In non-CNS cancer 
controls, intervention adherence was 92% for the introduc-
tion and 92, 81, 73, 65, and 54% for modules 1 through 5, 
respectively.
Reasons reported for not completing the program did not 
differ between the groups (p > 0.05). The most common rea-
sons were: course did not meet their needs, no need for the 
program anymore, or different kind of treatment preferred 
(44% glioma; 58% non-CNS); no reason provided (28% gli-
oma; 25% non-CNS); disease progression (11% glioma; 8% 
non-CNS); and cognitive/technical difficulties (13% glioma 
only). Other reasons were: too burdensome (2% glioma); 
wrong timing (2% glioma); wanted to continue working on 
module 4 instead (2% non-CNS).
The patient satisfaction questionnaire was completed by 
37/82 glioma patients (of whom 62% had completed the 
intervention) and 12/26 non-CNS cancer controls (of whom 
75% had completed the intervention). Most patients said they 
had benefitted from participating (73% glioma; 67% non-
CNS), and that they thought the program was useful (92% in 
both groups) and informative (86% glioma; 92% non-CNS). 
The program’s content (78% glioma; 75% non-CNS) and 
readability (88% glioma; 92% non-CNS) were rated good to 
very good. Feedback from the coach was considered to be 
*p < 0.05
a One patient was diagnosed with a meningioma, this was discovered after randomization
b Other medication includes treatment for arthritis, antivirals, antibiotics, antimyotics, antihypertensives, cholesterol inhibitors, anticoagulants, 
non-opioid analgesics, antiemetics, antihistamines, stomach protectors, thyroid medication, antidiabetic agents, drugs for bowel and bladder 
function, calcium and vitamin supplements
c Disease status missing in one patient (glioma waiting list group)
d Two items of the EORTC QLQ BN20 were not administered by error; motor dysfunction and bladder control scores are missing
Table 1  (continued)
Glioma inter-
vention group
N = 45
Glioma waiting list 
control group
N = 44
P value Glioma total group
N = 82
Non-CNS 
control group
N = 26
P value
 Resection 41 (91.1%) 34 (77.3%)
Treatments received at start of study N (%)
 Radiation therapy 30 (66.7%) 29 (65.9%) 0.940
 Chemotherapy 18 (40.0%) 24 (54.5%) 0.169
 Cognitive complaints M (SD) 24.7 (6.6) 22.6 (5.9) 0.122
Disease-specific  symptomsd M (SD)
 Future uncertainty 42.6 (19.6) 52.1 (21.7) 0.033*
 Visual disorder 19.8 (20.4) 21.0 (19.8) 0.778
 Communication deficits 26.2 (23.0) 30.6 (23.9) 0.380
 Headaches 28.9 (27.2) 33.3 (33.7) 0.495
 Seizures 10.4 (21.1) 16.7 (24.4) 0.196
 Drowsiness 26.7 (27.2) 36.4 (28.6) 0.104
 Bothered by hair loss 11.9 (21.5) 17.4 (30.9) 0.325
 Bothered by itching skin 19.3 (27.1) 19.7 (27.2) 0.940
 Weakness of legs 10.4 (21.1) 10.6 (20.0) 0.957
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Fig. 3  Percentages of patients scoring above the cut-off for depres-
sion (CES-D ≥ 16), fatigue (CIS ≥ 76), and diminished HRQOL 
(MCS and PCS ≤ 40). a Glioma intervention group and glioma wait-
ing list control group. b Total glioma group and non-CNS cancer 
control group. CES-D Center for Epidemiological Studies—Depres-
sion Scale, CIS Checklist Individual Strength, MCS Short-Form 36 
Health Survey Mental Component Summary, PCS Short-Form 36 
Health Survey Physical Component Summary
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useful (81% glioma; 75% non-CNS). However, the majority 
of patients indicated that they did not believe their depres-
sive symptoms had reduced after the online program (57% 
glioma; 67% non-CNS).
Discussion
Contrary to our expectations there were no beneficial effects 
of the intervention on depressive symptoms in our sample 
of glioma patients with depressive symptoms. Similarly, we 
found no changes in depressive symptoms in non-CNS can-
cer controls, which may indicate that the lack of effect is 
not likely the result of disease-specific issues. We did find 
a moderate effect on fatigue when comparing the glioma 
intervention group with the waiting list control group. This 
indicates that the program may help patients tackle their 
fatigue—at least in the short term, as the effect was no 
longer observed after 12 weeks follow-up. Nevertheless, this 
finding is important as fatigue is one of the most commonly 
reported and debilitating symptoms in glioma [35, 36], and 
little evidence for effective interventions exists [37]. Of note, 
this effect did not hold in PP analyses, possibly due to the 
smaller sample size leading to poorer statistical power.
Unexpectedly, at 12 months follow-up the physical com-
ponent of HRQOL remained stable in glioma patients, while 
scores improved in non-CNS cancer controls. Both this find-
ing and the borderline significant effect on fatigue could, in 
Table 2  Results of analyses comparing the glioma intervention group with the glioma waiting list control group
CES-D Center for Epidemiological Studies—Depression Scale, CIS Checklist Individual Strength, ES effect size, ITT Intention to treat, PP per 
protocol, SF-36 MCS Short-Form 36 Health Survey Mental Component Summary, SF-36 PCS Short-Form 36 Health Survey Physical Compo-
nent Summary
* p < 0.05
Intention to treat Per protocol
Glioma 
intervention 
group
Glioma waiting 
list control 
group
P value, ES, 95% CI Glioma 
intervention 
group
Glioma waiting 
list control 
group
P value, ES, 95% CI
Depression (CES-D) M (SD)
 Baseline N = 45
21.96 (5.9)
N = 43
24.98 (6.9)
N = 35
21.51 (6.1)
N = 28
24.07 (6.6)
 After intervention N = 19
18.84 (6.4)
N = 34
23.09 (7.1)
p = 0.390, ES = 0.190, 
95% CI = − 4.49 to 2.67
N = 18
19.61 (5.7)
N = 26
23.50 (6.1)
p = 0.454, ES = 0.038, 95% 
CI = − 6.17 to 2.79
 After 12 weeks N = 19
19.63 (7.5)
N = 37
22.38 (6.3)
p = 0.614, ES = 0.042, 
95% CI = − 2.67 to 4.49
N = 18
19.89 (7.6)
N = 28
22.86 (5.7)
p = 0.954, ES = 0.012, 95% 
CI = − 3.82 to 4.05
Fatigue (CIS) M (SD)
 Baseline N = 45
88.27 (22.0)
N = 43
99.81 (18.4)
N = 35
91.06 (20.5)
N = 28
101.71 (18.4)
 After intervention N = 19
81.58 (25.8)
N = 33
99.39 (16.3)
p = 0.054* ES = 0.306, 
95% CI = − 17.63 to 
0.15
N = 18
83.94 (24.3)
N = 25
101.08 (16.2)
p = 0.112, ES = 0.327, 95% 
CI = − 18.13 to 1.93
 After 12 weeks N = 19
80.16 (27.0)
N = 37
96.00 (17.3)
p = 0.238, ES = 0.210, 
95% CI = − 3.85 to 
15.25
N = 18
79.94 (27.8)
N = 28
96.50 (16.5)
p = 0.310, ES = 0.298, 95% 
CI = − 5.35 to 16.59
Health-related quality of life (SF-36 MCS), M (SD)
 Baseline N = 45
36.71 (7.9)
N = 44
32.74 (9.4)
N = 35
36.99 (7.7)
N = 28
31.79 (10.4)
 After intervention N = 19
38.34 (10.3)
N = 34
32.97 (8.9)
p = 0.326, ES = 0.159, 
95% CI = − 2.08 to 6.20
N = 18
37.78 (10.3)
N = 26
31.38 (8.5)
p = 0.349, ES = 0.132, 95% 
CI = − 2.50 to 6.99
 After 12 weeks N = 19
40.23 (9.6)
N = 37
33.53 (9.9)
p = 0.433, ES = 0.310, 
95% CI = − 6.32 to 2.73
N = 18
40.56 (9.8)
N = 28
32.4 (8.9)
p = 0.431, ES = 0.325, 95% 
CI = − 7.24 to 3.13
Health-related quality of life (SF-36 PCS), M (SD)
 Baseline N = 45
47.63 (10.9)
N = 44
45.55 (9.1)
N = 35
46.88 (11.1)
N = 28
46.82 (9.5)
 After intervention N = 19
51.17 (11.4)
N = 34
46.95 (10.1)
p = 0.141, ES = 0.211, 
95% CI = − 1.07 to 7.36
N = 18
51.07 (11.7)
N = 26
48.47 (10.5)
p = 0.347, ES = 0.239, 95% 
CI = − 2.48 to 6.98
 After 12 weeks N = 19
48.57 (9.8)
N = 37
47.25 (10.7)
p = 0.993, ES = 0.075, 
95% CI = − 4.01 to 4.04
N = 18
48.16 (9.9)
N = 28
47.43 (11.5)
p = 0.882, ES = 0.063, 95% 
CI = − 5.08 to 4.38
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Table 3  Results of analyses comparing the total glioma group with the non-CNS control group
Intention to treat Per protocol
Glioma total 
group
Non-CNS control 
group
P value, ES, 95% CI Glioma total 
group
Non-CNS control 
group
P value, ES, 95% 
CI
Depression (CES-D) M (SD)
 Baseline N = 82
22.14 (6.1)
N = 26
25.08 (6.6)
N = 63
22.11 (5.9)
N = 24
25.08 (6.7)
 After interven-
tion
N = 42
19.52 (7.5)
N = 13
20.31 (6.3)
p = 0.267, ES = 0.300
95% CI = − 1.70 to 
6.09
N = 38
19.82 (6.9)
N = 13
20.31 (6.3)
p = 0.272, 
ES = 0.401, 
95% CI = − 1.75 
to 6.18
 After 12 weeks N = 41
20.85 (8.5)
N = 12
25.41 (7.1)
p = 0.467, ES = 0.302, 
95% CI = − 6.36 to 
2.93
N = 38
20.42 (8.4)
N = 12
25.42 (7.1)
p = 0.418, 
ES = 0.218, 
95% CI = − 6.66 
to 2.78
 After 12 months N = 35
18.60 (9.3)
N = 7
18.14 (7.0)
p = 0.390, ES = 0.499, 
95% CI = − 3.31 to 
8.42
N = 33
17.85 (9.0)
N = 7
18.14 (6.9)
p = 0.447, 
ES = 0.433, 
95% CI = − 3.76 
to 8.00
Fatigue (CIS) M (SD)
 Baseline N = 82
91.76 (20.2)
N = 26
96.85 (13.5)
N = 63
93.48 (18.9)
N = 24
96.75 (13.0)
 After interven-
tion
N = 42
89.74 (24.9)
N = 13
86.74 (18.1)
p = 0.208, ES = 0.426, 
95% CI = − 3.59 to 
16.35
N = 38
91.02 (23.5)
N = 13
86.69 (18.1)
p = 0.241, 
ES = 0.430, 
95% CI = − 4.06 
to 16.00
 After 12 weeks N = 41
90.12 (27.2)
N = 12
90.42 (15.2)
p = 0.503, ES = 0.252, 
95% CI = − 8.16 to 
16.54
N = 38
88.53 (27.1)
N = 12
90.42 (15.2)
p = 0.716, 
ES = 0.078, 
95% 
CI = − 10.12 to 
14.69
 After 12 months N = 34
87.94 (24.2)
N = 7
94.57 (23.7)
p = 0.587, ES = 0.081, 
95% CI = − 20.69 to 
11.78
N = 32
86.19 (23.9)
N = 7
94.57 (23.7)
p = 0.438, 
ES = 0.289, 
95% 
CI = − 22.60 to 
9.86
Health-related quality of life (SF-36 MCS) M (SD)
 Baseline N = 82
35.27 (9.0)
N = 26
29.73 (7.3)
N = 63
34.94 (8.5)
N = 24
29.58 (7.2)
 After interven-
tion
N = 41
36.79 (10.2)
N = 13
35.20 (8.3)
p = 0.159, ES = 0.455, 
95% CI = − 8.43 to 
1.40
N = 37
36.53 (9.9)
N = 13
35.20 (8.3)
p = 0.201, 
ES = 0.489, 
95% CI = − 8.10 
to 1.72
 After 12 weeks N = 41
37.42 (10.2)
N = 12
33.48 (13.0)
p = 0.385, ES = 0.184, 
95% CI = − 7.50 to 
2.92
N = 38
37.92 (10.2)
N = 12
33.48 (13.0)
p = 0.478, 
ES = 0.112, 
95% CI = − 7.26 
to 3.42
 After 12 months N = 35
39.83 (9.2)
N = 7
33.34 (10.4)
p = 0.601, ES = 0.109, 
95% CI = – 5.12 to 
8.80
N = 33
40.24 (9.3)
N = 7
33.34 (10.4)
p = 0.545, 
ES = 0.187, 
95% CI = − 4.89 
to 9.19
Health-related quality of life (SF-36 PCS) M (SD)
 Baseline N = 82
47.46 (10.7)
N = 26
44.44 (9.6)
N = 63
47.13 (11.2)
N = 24
44.52 (9.9)
 After interven-
tion
N = 41
50.05 (10.7)
N = 13
47.81 (11.7)
p = 0.734, ES = 0.074, 
95% CI = − 5.24 to 
3.70
N = 37
50.06 (11.24)
N = 13
47.81 (11.7)
p = 0.822, 
ES = 0.033, 
95% CI = − 4.93 
to 3.92
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part, be explained by a bias due to participant dropout. As 
only 31% of non-CNS cancer controls and ~ 39% of glioma 
patients completed the 12 month assessments, it seems 
possible that those with worse physical HRQOL discon-
tinued study participation, leading to an overestimation of 
HRQOL—a known issue in glioma studies [38] which could 
apply to non-CNS cancer groups as well.
We encountered great difficulties regarding recruit-
ment, attrition, and adherence. Despite nation-wide recruit-
ment efforts spanning a 3.5 years period, only 308 patients 
responded to the study information of whom 40% could be 
recruited. This is a low participation rate considering that 
in general, 60% of cancer patients participate in interven-
tion studies to reduce distress [39]. The final sample con-
sisted of only ~ 71 and ~ 41% of the required sample size for 
glioma patients and non-CNS cancer controls, respectively. 
Moreover, attrition was higher than anticipated with previ-
ous studies reporting ~ 31–50% dropout [40, 41]. Adherence 
to the intervention was low, which is a common problem in 
(internet-based) psychological intervention studies [40, 42].
We aimed to perform this RCT with high external valid-
ity, using few exclusion criteria. Patients were allowed to 
use antidepressants and/or mental health care services. 
Although there were no statistically significant differences 
between study arms, about 25–29% of glioma patients and 
42% of non-CNS cancer controls used other mental health 
care services (e.g., psychologist, psychiatrist, or counsellor). 
This may have attenuated possible effects of the interven-
tion. Over half of our glioma patient sample had a low-grade 
tumor. While there is no reason to assume depressive symp-
toms might differ between those with low- or high-grade 
tumors, high-grade gliomas are more common and patients 
with higher grade tumors tend to have a different disease 
burden [43]. Our study sample may therefore not be a com-
pletely accurate representation of the general glioma patient 
population. Moreover, due to the nature of the intervention 
we do not know whether patients required any help from 
their family caregiver to complete the program.
Despite the study’s shortcomings, it is the first RCT to 
explore the effectiveness of online psychological treatment 
in glioma patients. Similar studies in other neurological/
oncological patient groups yielded mixed results. In a small 
sample of patients with chronic spinal cord injury, an online 
CBT-based program reduced distress in both the interven-
tion group and a waiting list control group, but no differ-
ence was found between the groups [44]. Other supportive 
internet-based interventions have shown positive effects on 
HRQOL in cancer patients [45]. Especially programs based 
on CBT appear to be effective in alleviating depressive 
symptoms in patients with chronic illness [46, 47]. As PST 
is a low-intensity form of CBT, a more intensive treatment 
might be required to effectively treat depressive symptoms 
in glioma patients. The internet-based program might still 
be useful as a part of stepped care, where interventions of 
increased intensity are introduced step by step. Indeed, this 
concept has been found effective in other cancer populations 
[48, 49]. However intensive therapies may not be feasible for 
all glioma patients, in particular those with more cognitive 
deficits and fatigue, hence other avenues for support should 
be explored as well.
To conclude, this RCT showed that in glioma patients, 
a guided internet-based PST is not effective in reducing 
depressive symptoms or improving HRQOL, but it seems 
to have a positive effect on fatigue. In part, the lack of statis-
tically significant effects could be explained by poor statisti-
cal power, low adherence, and high attrition rates. Further 
research is required to determine effective treatments for 
depressive symptoms in glioma patients.
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Table 3  (continued)
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Non-CNS control 
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